nach oben

Erschienen in:

2020 | OriginalPaper | Buchkapitel

11. Major Nano-based Products: Nanomedicine, Nanosensors, and Nanodiagnostics

verfasst von : Firdos Alam Khan

Erschienen in: Applications of Nanomaterials in Human Health

Verlag: Springer Singapore

Einloggen

Aktivieren Sie unsere intelligente Suche, um passende Fachinhalte oder Patente zu finden.

search-config

KI-gestützte Suche

Aus

Abstract

Nanomedicine is a very rapidly evolving field which has many biological, biomedical, and healthcare applications. Due to various beneficial properties of the nanomaterials, such as vast surface area, high biocompatibility, and biodistribution properties, these nanoparticles have been used to develop many useful products. Many of these nano-based products are under various developmental stages and many nanodrugs have been reported to have entered clinical phases of testing for various treatment conditions. In this chapter, we discuss some of the major nanoproducts which are developed for the treatment, diagnosis, and biosensing purposes.

Sie haben noch keine Lizenz? Dann Informieren Sie sich jetzt über unsere Produkte:

Springer Professional "Wirtschaft+Technik"

Online-Abonnement

Mit Springer Professional "Wirtschaft+Technik" erhalten Sie Zugriff auf:

über 102.000 Bücher
über 537 Zeitschriften

aus folgenden Fachgebieten:

Automobil + Motoren
Bauwesen + Immobilien
Business IT + Informatik
Elektrotechnik + Elektronik
Energie + Nachhaltigkeit
Finance + Banking
Management + Führung
Marketing + Vertrieb
Maschinenbau + Werkstoffe
Versicherung + Risiko

Jetzt Wissensvorsprung sichern!

Jetzt informieren

Springer Professional "Technik"

Online-Abonnement

Mit Springer Professional "Technik" erhalten Sie Zugriff auf:

über 67.000 Bücher
über 390 Zeitschriften

aus folgenden Fachgebieten:

Automobil + Motoren
Bauwesen + Immobilien
Business IT + Informatik
Elektrotechnik + Elektronik
Energie + Nachhaltigkeit
Maschinenbau + Werkstoffe

Jetzt Wissensvorsprung sichern!

Jetzt informieren

Vorheriges Kapitel Application of Nanomaterials in Treatment of Endocrine Diseases

Nächstes Kapitel NANOMATERIALS: Global Research Publication, Research Quality, and Patent Trends

Ahn HK, Jung M, Sym SJ et al (2014) A phase II trial of Cremorphor EL-free paclitaxel (Genexol-PM) and gemcitabine in patients with advanced non–small-cell lung cancer. Cancer Chemother Pharmacol 74:277–282

Awada A, Garcia AA, Chan S et al (2013) Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study. Lancet Oncol 14(12):1216–1225

Bansal S, Bansal M, Kumria R (2012) Nanocrystals: current strategies and trends. Int J Res Pharm Biomed Sci 3:406–419

Bobo D, Robinson KJ, Islam J et al (2016) Nanoparticle-based medicines: a review of FDA-approved materials and clinical trials to date. Pharm Res 33(10):2373–2387

Bruchez M Jr, Moronne M, Gin P et al (1998) Semiconductor nanocrystals as fluorescent biological labels. Science 281:2013–2016

Caster JM, Patel AN, Zhang T, Wang A (2017) Investigational nanomedicines in 2016: a review of nanotherapeutics currently undergoing clinical trials. Wiley Interdiscip Rev Nanomed Nanobiotechnol 9(1). https://doi.org/10.1002/wnan

Centerwatch (n.d.) 2017 FDA approved drugs. Available at: www.center-watch.com/drug-information/fda-approved-drugs. Accessed 25 Oct 2017

Clancy JP, Dupont L, Konstan MW et al (2013) Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection. Thorax 68:818–825

ClinicalTrials.gov (n.d.). Available at: https://clinicaltrials.gov. Accessed 25 Oct 2017

Cohen CR, Brown J, Moscicki AB et al (2011) A phase 1 randomized placebo controlled trial of the safety of 3% SPL7013 Gel (VivaGel) in healthy young women administered twice daily for 14 days. PLoS One 6(1):e16258

Cortes JE, Goldberg SL, Feldman EJ et al (2015) Phase II, multicenter, randomized trial of CPX-351 (cytarabine: daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML. Cancer 121:234–242

Desai N, Trieu V, Yao ZW et al (2006) Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of Cremophor-free, albumin-bound paclitaxel, ABI-007, compared with Cremophor-based paclitaxel. Clin Cancer Res 12(4):1317–1324

Dipetrillo T, Milas L, Evans D et al (2006) Paclitaxel poliglumex (PPXXyotax) and concurrent radiation for esophageal and gastric cancer: a phase 1 study. Am J Clin Oncol 29:376–379

Dipetrillo T, Suntharalingam M, Ng T et al (2012) Neoadjuvant paclitaxel poliglumex, cisplatin, and radiation for esophageal cancer: a phase 2 trial. Am J Clin Oncol 35:64–67

Elamanchili P, Diwan M, Cao M, Samuel J (2004) Characterization of poly(D, L-lactic-co-glycolic acid) based nanoparticulate system for enhanced delivery of antigens to dendritic cells. Vaccine 22:2406–2412

Fleischman T (2016) Cancer killers: C dots show ability to induce cell death in tumors. Cornell Chronicle. 26 Sep 2016. Available at: http://news.cornell.edu/stories/2016/09/cancer-killers-c-dots-show-ability-induce-cell-death-tumors. Accessed 9 Aug 2017

Flexion Therapeutics, Inc (n.d.) Our product: Zilretta (triamcinolone acetonide extended release formulation). Available at: https://flexiontherapeutics.com/our-product. Accessed 25 Oct 2017

Food and Drug Administration (2017) Novel drug approvals for 2017. 25 Oct 2017. Available at: www.fda.gov/drugs/developmentapprovalprocess/druginnovation/ucm537040. Accessed 25 Oct 2017

Foss F (2006) Clinical experience with denileukin diftitox (Ontak). Semin Oncol 33(1 Suppl 3):S11–S16

Fuentes AC, Szwed E, Spears CD et al (2015) Denileukin diftitox (Ontak) as maintenance therapy for peripheral T-cell lymphomas: three cases with sustained remission. Case Pep Oncol Med 2015:123756. https://doi.org/10.1155/2015/123756CrossRef

Gabizon A, Catane R, Uziely B et al (1994) Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethyleneglycol-coated liposomes. Cancer Res 54(4):987–992

Gao L, Liu G, Ma J et al (2013) Application of drug nanocrystal technologies on oral drug delivery of poorly soluble drugs. Pharm Res 30:307–324

Geho WB, Geho HC, Lau JR, Gana TJ (2009) Hepatic directed vesicle insulin: a review of formulation development and preclinical evaluation. J Diabetes Sci Technol 3:1451–1459

Geho WB, Rosenberg LN, Schwartz SL et al (2014) A single-blind, placebo-controlled, dose ranging trial of oral hepatic-directed vesicle insulin add-on to oral antidiabetic treatment in patients with type 2 diabetes mellitus. J Diabetes Sci Technol 8:551–559

Glenn GM, Fries LF, Smith G et al (2015) Modeling maternal fetal RSV F vaccine induced antibody transfer in Guinea pigs. Vaccine 33:6488–6492

Gregory AE, Titball R, Williamson D (2013) Vaccine delivery using nanoparticles. Front Cell Infect Microbiol 3:13

Havel HA (2016) Where are the nanodrugs? An industry perspective on development of drug products containing nanomaterials. AAPS J 18(6):1351–1353

Havel H, Finch G, Strode P et al (2016) Nanomedicines: from bench to bedside and beyond. AAPS J 18(6):1373–1378

Hu X, Miller L, Richman S et al (2012) A novel PEGylated interferon beta-1a for multiple sclerosis: safety, pharmacology, and biology. J Clin Pharmacol 52(6):798–808

Jeyapalan S, Boxerman J, Donahue J et al (2014) Paclitaxel poliglumex, temozolomide, and radiation for newly diagnosed high-grade glioma: a Brown University Oncology Group study. Am J Clin Oncol 37:444–449

Kim TY, Kim DW, Chung JY et al (2004) Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. Clin Cancer Res 10:3708–3716

Kim DW, Kim SY, Kim HK et al (2007) Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non–small-cell lung cancer. Ann Oncol 18:2009–2014

Lancet JE, Cortes JE, Hogge DE et al (2014) Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs. cytarabine/daunorubicin in older adults with untreated AML. Blood 123:3239–3246

Lee KS, Chung HC, Im SA et al (2008) Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer. Breast Cancer Res Treat 108:241–250

Libutti SK, Paciotti GF, Byrnes AA et al (2010) Phase I and pharmacokinetic studies of CYT-6091, a novel PEGylated colloidal gold-rhTNF nanomedicine. Clin Cancer Res 16:6139–6149

Maier-Hauff K, Ulrich F, Nestler D et al (2011) Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme. J Neuro-Oncol 103(2):317–324

Morgan MA, Darcy KM, Rose PG et al (2008) Paclitaxel poliglumex and carboplatin as first-line therapy in ovarian, peritoneal, or fallopian tube cancer: a phase 1 and feasibility trial of the Gynecologic Oncology Group. Gynecol Oncol 110:329–335

O’Loughlin J, Millwood IY, McDonald HM et al (2010) Safety, tolerability, and pharmacokinetics of SPL7013 gel (VivaGel): a dose ranging, phase 1 study. Sex Transm Dis 37:100–104

Ortega A, Farah S, Tranque P et al (2015) Antimicrobial evaluation of quaternary ammonium polyethyleneimine nanoparticles against clinical isolates of pathogenic bacteria. IET Nanobiotechnol 9:342–348

Price CF, Tyssen D, Sonza S et al (2011) SPL7013 Gel (VivaGel) retains potent HIV-1 and HSV-2 inhibitory activity following vaginal administration in humans. PLoS One 6(9):e24095

Sabbatini P, Sill MW, O’Malley D et al (2008) A phase II trial of paclitaxel poliglumex in recurrent or persistent ovarian or primary peritoneal cancer (EOC): a Gynecologic Oncology Group study. Gynecol Oncol 111(3):455–460

Stanberry LR, Simon JK, Johnson C et al (2012) Safety and immunogenicity of a novel nanoemulsion mucosal adjuvant W₈₀5EC combined with approved seasonal influenza antigens. Vaccine 30:307–316

Svenson S, Tomalia DA (2005) Dendrimers in biomedical applications—reflections on the field. Adv Drug Deliv Rev 57:2106–2129

Valle JW, Armstrong A, Newman C et al (2011) A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction. Investig New Drugs 29:1029–1037

Ventola CL (2012a) The nanomedicine revolution: part 1: emerging concepts. P T 37(9):512–525

Ventola CL (2012b) The nanomedicine revolution: part 2: current and future clinical applications. P T 37(10):582–591

Ventola CL (2017) Progress in nanomedicine: approved and investigational nanodrugs. P T 42(12):742–755

Verschraegen CF, Skubitz K, Daud A et al (2009) A phase 1 and pharmacokinetic study of paclitaxel poliglumex and cisplatin in patients with advanced solid tumors. Cancer Chemother Pharmacol 63:903–910

Weiss GJ, Chao J, Neidhart JD et al (2013) First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies. Investig New Drugs 31:986–1000

Weissig V, Pettinger TK, Murdock N (2015) Nanopharmaceuticals (part 1): products on the market. Int J Nanomedicine 10:1245–1257

Wolfram J, Zhu M, Yang Y et al (2015) Safety of nanoparticles in medicine. Curr Drug Targets 16(14):1671–1681

Zhu M, Wang R, Nie G (2014) Applications of nanomaterials as vaccine adjuvants. Hum Vaccin Immunother 10:2761–2774

Titel: Major Nano-based Products: Nanomedicine, Nanosensors, and Nanodiagnostics
verfasst von: Firdos Alam Khan
Verlag: Springer Singapore
Buch: Applications of Nanomaterials in Human Health
Print ISBN: 978-981-15-4801-7

Electronic ISBN: 978-981-15-4802-4

Copyright-Jahr: 2020
DOI: https://doi.org/10.1007/978-981-15-4802-4_11

Premium Partner

Marktübersichten

Die im Laufe eines Jahres in der „adhäsion“ veröffentlichten Marktübersichten helfen Anwendern verschiedenster Branchen, sich einen gezielten Überblick über Lieferantenangebote zu verschaffen.

Zur Marktübersicht